Home - Actinogen

Listen to conference call held on 1 Oct 2019 >

Following the recent ASX Announcement on 1 Oct 2019, Actinogen Medical held a conference call to give an update on the results from the XanaHES trial. “These are the results we have been looking for. They are hugely important for the development of Xanamem and for the potential for Xanamem to treat Alzheimer’s disease and other conditions associated with cognitive impairment” said Dr Bill Ketelbey

Listen to interview

Dr Bill Ketelbey, CEO Actinogen Medical provides an update on the Xanamem Clinical Development Program. “…We are now seeing results from the nine studies that are running in parallel to XanADu. These studies are going to help interpret the XanADu results and will develop a comprehensive database for Xanamem itself that will allow us in the next few months to develop a good solid strategic plan for the future development of Xanamem…” said Dr Bill Ketelbey

View ASX Announcement and presentation

Actinogen is delighted to announce results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The Company hosted a conference call at 10:30am (AEST) on Tuesday 1st October 2019. The presentation referred to in the call, is attached to this announcement.

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive impairment associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.

Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.

Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.

Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.

"Given the growing number of people with Alzheimer's and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer's patients, and their carers and families worldwide."

DR BILL KETELBEY, CEO & MANAGING DIRECTOR

Board of Directors

DR. Geoff Brooke

Chairman